ClinicalTrials.gg
Active, not recruitingNCT06637501Updated Jul 9, 2026

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

A Phase 2 interventional study of Sonrotoclax and Zanubrutinib in Chronic Lymphocytic Leukemia, sponsored by BeOne Medicines. Active, not recruiting at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by BeOne Medicines · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing sonrotoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 11 under way, 4 of them phase 3. sonrotoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
7th of 11
94 · median 100
Started
2024
with 1 other
Phase 2
5 of 11
3 open now
Primary completion
2026-11
later than 1 of 10 live
Registered
4th of 11
by date
Lead sponsor
5 of 11
BeOne Medicines

Among the 11 studies testing sonrotoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 7th largest by planned enrollment, is one of 2 that started in 2024, is one of 5 in phase 2, reaches primary completion later than 1 of the 10 other live ones, and was the 4th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 11 studies testing sonrotoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About sonrotoclax

sonrotoclax: first FDA approval 2026 (BEQALZI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing sonrotoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.

Read the detailed description

This study will test how effective and safe Sonrotoclax plus Zanubrutinib treatment compared with Zanubrutinib alone in participants with previously untreated chronic lymphocytic leukemia (CLL).

The main goals of the study are to determine how many participants may no longer have evidence of cancer or have some improvement in the signs and symptoms of cancer after treatment and to determine what adverse events, or side effects, patients might experience.

Sonrotoclax is an experimental drug that works by blocking a protein called B-cell lymphoma-2 (Bcl-2). This protein helps certain types of blood tumor cells to survive and grow. When Sonrotoclax blocks Bcl-2 it slows down or stops the growth of tumor cells and helps them die. This can lead to improvements in patients with CLL disease.

Zanubrutinib is a commercialized product that works by blocking a protein called Bruton's tyrosine kinase (BTK) and controlling the activity and survival of malignant B cells. Zanubrutinib has received approval in over 65 countries/regions worldwide for the treatment of adult participants with B cell malignancies, including CLL.

The study will enroll approximately 87 participants who will be randomly assigned by a computer program to receive one of the following treatments: sonrotoclax + zanubrutinib or zanubrutinib.

The study will take place at multiple centers worldwide. The overall time to participate in this study is approximately 5 years.

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • CLL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Previously untreated adult patient ≥ 18 years with a confirmed diagnosis of CLL.
  2. CLL requiring treatment as per pre-defined criteria.
  3. (ECOG) Performance Status score of 0,1, or 2.
  4. by computed tomography (CT)/magnetic resonance imaging (MRI).
  5. Adequate marrow function.
  6. Adequate liver function as indicated by (AST) alanine aminotransferase (ALT) and serum total .
  7. Adequate renal function.
  8. > 6 months.
  9. Signed and able to comply with the study protocol in the investigator's judgment.
  10. Women of must be willing to use a highly effective method of for the duration of the study and for ≥ 90 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
  2. Known central nervous system involvement
  3. Received previous systemic treatment for CLL
  4. cardiovascular disease
  5. Severe or debilitating pulmonary disease
  6. History of prior
  7. Active fungal, bacterial, and/or viral infection requiring systemic therapy
  8. Positive (HIV) serology (HIVAb) status or serologic status reflecting active or C infection
  9. Uncontrolled hemolytic anemia or immune thrombocytopenia requiring treatment
  10. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention
  11. History of stroke or intracranial hemorrhage ≤ 6 months before the first dose of study treatment
  12. Unable to swallow capsules or tablets or diseases significantly affecting GI function
  13. to zanubrutinib, sonrotoclax, or any of its
  14. Use of agents within the last 4 weeks before screening
  15. Pregnant and lactating females

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    Arm A: Combination Therapy: Sonrotoclax + Zanubrutinib

    Participants will receive sonrotoclax in combination with zanubrutinib daily for a fixed duration of 15 cycles.

    Drug: Sonrotoclax · Drug: Zanubrutinib

  • Active comparator
    Arm B: Monotherapy: Zanubrutinib

    Participants will receive zanubrutinib monotherapy daily until disease progression or unacceptable toxicity, whichever occurs first.

    Drug: Zanubrutinib

Interventions

  • Administered orally

    Also known as: BGB-11417

  • Administered orally

    Also known as: BRUKINSA, BGB-3111

06

What researchers measure

Primary outcomes

  1. Complete Response (CR)/ Complete Response with Incomplete Bone Marrow Recovery (CRi) Rate

    Best CR/CRi rate per the Independent Review Committee (IRC) response assessment using the 2018 International Workshop on Chronic Lymphocytic Leukemia guidelines with modification for treatment-related lymphocytosis for participants with CLL

    Time frame: Month 16

Secondary outcomes

  1. Undetectable Minimal Residual Disease at < 10^-4Sensitivity (uMRD4) Rate

    uMRD4 rate measured in both peripheral blood and bone marrow aspirate

    Time frame: Month 16

  2. CR/CRi Rate per Investigator Response Assessment

    CR/CRi Rate (CRR) is defined as the percentage of participants with best overall response of CR or CRi

    Time frame: Month 16

  3. Overall Response Rate (ORR) per IRC and Investigator Response Assessment

    ORR is defined as the percentage of participants achieving overall response (CR+CRi+partial response \[PR\]+nodular PR) per the IRC and the investigator response assessment.

    Time frame: Up to 66 Months

  4. Duration of Response (DOR) per Investigator Response Assessment

    DOR is defined as the time from first qualifying response (PR, nodular PR, CR,or CRi) until CLL progression or death.

    Time frame: Up to 66 Months

  5. Time to Response (TTR) per IRC and Investigator Response Assessment

    TTR is defined as the time from treatment initiation to the first documentation of response

    Time frame: Up to 66 Months

  6. Landmark Progression-free Survival Rate at 24 Months per Investigator Assessment

    The 24-month landmark PFS rate is defined as the percentage of participants who remain alive and progression-free at 24 months since the start of treatment

    Time frame: 24 Months

  7. Progression-free Survival (PFS) per Investigator Response Assessment

    PFS is defined as the time from the start of treatment to the first documentation of disease progression or death, whichever occurs first

    Time frame: Up to 66 Months

  8. Overall Survival (OS)

    OS is defined as the time from treatment initiation to death due to any cause

    Time frame: Up to 66 Months

  9. Number of Participants with Adverse Events (AEs)

    Safety will be assessed by monitoring and recording of all treatment emergent adverse events (AEs) graded by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Time frame: From first dose of study drug to 30 days after last dose; up to 66 months for Arm A and Arm B

07

Study locations

32 sites
08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's planned 24 months is below that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Nov 14, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Sep 2029
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06637501
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Nov 14, 2024
Primary completion
Nov 2026 (estimated)
Completion
Sep 2029 (estimated)
Last update
Jul 9, 2026

Study contacts

Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonrotoclax

Start the discussion